BioLASCO Taiwan Co., Ltd.

Total Valuation

BioLASCO Taiwan Co., Ltd. carries a market capitalization of 760.68M, placing it among publicly traded companies globally. Its enterprise value stands at 750.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

BioLASCO Taiwan Co., Ltd. currently has 25.61M shares outstanding.

Valuation Ratios

BioLASCO Taiwan Co., Ltd. trades at a trailing price-to-earnings ratio of 18.69. The price-to-sales ratio is 3.02, and the price-to-book ratio stands at 2.64.

Enterprise Valuation

On an enterprise value basis, BioLASCO Taiwan Co., Ltd. trades at an EV/EBITDA multiple of 15.59 and an EV/FCF ratio of 10.40. The EV/Sales ratio of 2.86 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.59 provides insight into valuation relative to core operating earnings.

Financial Position

BioLASCO Taiwan Co., Ltd. maintains a current ratio of 3.93, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.45, indicating elevated leverage, while an interest coverage ratio of 23.68 demonstrates strong ability to service its debt obligations.

Financial Efficiency

BioLASCO Taiwan Co., Ltd. posts a return on equity of 14.04 and a return on invested capital of 7.39.

Taxes

Over the trailing twelve months, BioLASCO Taiwan Co., Ltd. has paid 7.14M in income taxes, reflecting an effective tax rate of 14.40.

Stock Price Statistics

BioLASCO Taiwan Co., Ltd.'s stock has declined approximately -12.90323% over the past 52 weeks. The 50-day moving average sits at 29.55, while the 200-day moving average is 30.50.

Income Statement

Over the trailing twelve months, BioLASCO Taiwan Co., Ltd. generated 262.66M in revenue and converted that into 42.43M in net income, yielding earnings per share of 1.66. EBITDA reached 48.11M, while operating income came in at 48.11M.

Balance Sheet

BioLASCO Taiwan Co., Ltd. holds 136.41M in cash and equivalents against 93.59M in total debt, resulting in a net debt position of 10.84M. Total book value stands at 300.88M, with working capital of 157.42M providing operational flexibility.

Cash Flow

BioLASCO Taiwan Co., Ltd. produced 48.71M in operating cash flow over the past twelve months. After subtracting -21.65M in capital expenditures, free cash flow totaled 27.06M - equivalent to 1.06 per share.

Margins

BioLASCO Taiwan Co., Ltd. operates with a gross margin of 39.89, reflecting its pricing power and cost economics. The operating margin of 18.32 and net profit margin of 16.15 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

BioLASCO Taiwan Co., Ltd.'s most recent stock split took place on July 30, 2018 with a 200:211 split ratio.

Scores

BioLASCO Taiwan Co., Ltd. posts an Altman Z-Score of 4.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.